RIL
KROS icon

Rothschild Investment LLC’s Keros Therapeutics KROS Stock Holding History

Rothschild Investment LLC’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.72K Buy
441
+211
+92% +$2.35K ﹤0.01% 2306
2026
Q1 		$2.54K Buy
230
+66
+40% +$1.02K ﹤0.01% 2436
2025
Q4 		$3.34K Sell
164
-11
-6% -$193 ﹤0.01% 2103
2025
Q3 		$2.77K Hold
175
– – ﹤0.01% 2020
2025
Q2 		$2.34K Sell
175
-5
-3% -$68 ﹤0.01% 1967
2025
Q1 		$1.83K Buy
180
+145
+414% +$1.68K ﹤0.01% 1949
2024
Q4 		$554 Sell
35
-5
-13% -$260 ﹤0.01% 2491
2024
Q3 		$2.32K Buy
40
+25
+167% +$1.24K ﹤0.01% 1646
2024
Q2 		$686 Buy
15
+10
+200% +$537 ﹤0.01% 1851
2024
Q1 		$331 Buy
+5
New +$296 ﹤0.01% 1512

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Rothschild Investment LLC's KROS Position: Q2 2026 in Review

Rothschild Investment LLC increased its Keros Therapeutics (KROS) stake by 92% in Q2 2026, buying an estimated $2.35K and bringing the position to 441 shares worth $4.72K. The position accounts for ﹤0.01% of the portfolio, ranked #2306.

Rothschild Investment LLC first reported a position in KROS in Q1 2024 and has held it in 10 quarters since. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Rothschild Investment LLC held 441 shares of Keros Therapeutics worth $4.72K as of Q2 2026.
  • Rothschild Investment LLC bought 211 Keros Therapeutics shares in Q2 2026, an estimated $2.35K.
  • Keros Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #2306 holding.
  • Rothschild Investment LLC first reported a position in Keros Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.